Sitagliptin is used for: Type 2 diabetes mellitus.
Recorded in the NepalDoc medicine catalog for Sitagliptin.
JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
From the U.S. FDA-approved label for Sitagliptin. Full label: DailyMed.
JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
From the U.S. FDA-approved label for Sitagliptin. Full label: DailyMed.
The recommended dose of JANUVIA is 100 mg once daily. JANUVIA can be taken with or without food. Dosage adjustment is recommended for patients with eGFR less than 45 mL/min/1.73 m 2.
Directions from the U.S. FDA-approved label for Sitagliptin — your doctor or pharmacist may advise differently.
History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema
Excerpt from the U.S. FDA-approved label for Sitagliptin. Talk to a pharmacist or doctor before use.
Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA., Heart failure: Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of JANUVIA in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms., Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis.
Warnings and precautions excerpt from the U.S. FDA-approved label for Sitagliptin — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse reactions are also discussed elsewhere in the labeling: Pancreatitis, Heart Failure, Acute Renal Failure, Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues, Hypersensitivity Reactions, Severe and Disabling Arthralgia, Bullous Pemphigoid Adverse reactions reported in ≥5% of patients treated with JANUVIA and more commonly than in patients treated with placebo are: upper respiratory…
Excerpt from the U.S. FDA-approved label for Sitagliptin — not a complete list. Talk to a pharmacist or doctor about side effects.
35 brands · 15 makers in the NepalDoc catalog — see the full Sitagliptin guide →
Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F).
Storage information from the U.S. FDA-approved label for Sitagliptin.
What is CITAZIP?
CITAZIP 25MG Tablet is a Sitagliptin medicine made by CTL Pharmaceuticals Pvt. Ltd. It comes as 25MG Tablet.
What is CITAZIP used for?
Sitagliptin is used for Type 2 diabetes mellitus.
What is the generic name of CITAZIP?
The generic name of CITAZIP is Sitagliptin.
Which brands of Sitagliptin are available in Nepal?
35 brands of Sitagliptin are listed in the NepalDoc catalog, from 15 makers — including ARROW 50MG Tablet, CITAZIP 100MG Tablet, CITAZIP 50MG Tablet, Glipsi 100mg Tablet, Glipsi 50mg Tablet, Gliptin 100mg Tablet.
What are the side effects of Sitagliptin?
The following adverse reactions are also discussed elsewhere in the labeling: Pancreatitis, Heart Failure, Acute Renal Failure, Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues, Hypersensitivity Reactions, Severe and Disabling Arthralgia, Bullous Pemphigoid Adverse reactions reported in ≥5% of patients treated with JANUVIA and more commonly than in patients treated with placebo are: upper respiratory…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
